

# Hongyun Zhao

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9645165/publications.pdf>

Version: 2024-02-01

83  
papers

2,619  
citations

304602

22  
h-index

223716

46  
g-index

85  
all docs

85  
docs citations

85  
times ranked

4186  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. <i>Lancet Oncology</i> , 2018, 19, 1338-1350.                            | 5.1 | 337       |
| 2  | EBV-driven LMP1 and IFN- $\beta$ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy. <i>Oncotarget</i> , 2014, 5, 12189-12202.  | 0.8 | 324       |
| 3  | Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5015-5026.                                     | 3.2 | 143       |
| 4  | Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer. <i>Scientific Reports</i> , 2016, 6, 20090.  | 1.6 | 138       |
| 5  | Ratio of C-Reactive Protein/Albumin is An Inflammatory Prognostic Score for Predicting Overall Survival of Patients with Small-cell Lung Cancer. <i>Scientific Reports</i> , 2015, 5, 10481.  | 1.6 | 126       |
| 6  | Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations. <i>PLoS ONE</i> , 2014, 9, e85245.  | 1.1 | 125       |
| 7  | Education and lung cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2019, 48, 743-750.   | 0.9 | 73        |
| 8  | The genomic landscape of Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinoma. <i>Nature Communications</i> , 2019, 10, 3108.   | 5.8 | 69        |
| 9  | PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival. <i>Oncotarget</i> , 2015, 6, 33019-33032.  | 0.8 | 69        |
| 10 | Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706). <i>Journal of Thoracic Oncology</i> , 2021, 16, 1533-1546.   | 0.5 | 64        |
| 11 | Advanced Lung Cancer Inflammation Index, a New Prognostic Score, Predicts Outcome in Patients With Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2015, 16, e165-e171.   | 1.1 | 60        |
| 12 | Impact of prior cancer history on the overall survival of patients newly diagnosed with cancer: A pan-cancer analysis of the SEER database. <i>International Journal of Cancer</i> , 2018, 143, 1569-1577.                          | 2.3 | 57        |
| 13 | The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer. , 2019, 7, 98.  |     | 53        |
| 14 | First-in-Human Phase I Study of ACO010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance. <i>Journal of Thoracic Oncology</i> , 2018, 13, 968-977.          | 0.5 | 50        |
| 15 | Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing. <i>Molecular Cancer</i> , 2019, 18, 7.   | 7.9 | 48        |
| 16 | PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy. <i>Translational Lung Cancer Research</i> , 2020, 9, 1258-1267.   | 1.3 | 47        |
| 17 | Osimertinib (AZD9291) Enhanced the Efficacy of Chemotherapeutic Agents in ABCB1- and ABCG2-Overexpressing Cells <i>In Vitro</i> , <i>In Vivo</i> , and <i>Ex Vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1845-1858. | 1.9 | 43        |
| 18 | Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer. <i>JAMA Network Open</i> , 2020, 3, e2015748.   | 2.8 | 36        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Intratumoral heterogeneity as a predictive biomarker in anti-PD-(L)1 therapies for non-small cell lung cancer. <i>Molecular Cancer</i> , 2021, 20, 37.  | 7.9 | 36        |
| 20 | Comparison of the Prognostic Value of Systemic Inflammation Response Markers in Small Cell Lung Cancer Patients. <i>Journal of Cancer</i> , 2019, 10, 1685-1692.  | 1.2 | 34        |
| 21 | Development and validation of a nomogram for predicting the survival of patients with non-metastatic nasopharyngeal carcinoma after curative treatment. <i>Chinese Journal of Cancer</i> , 2016, 35, 98.  | 4.9 | 32        |
| 22 | Optimized selection of three major EGFR-TKIs in advanced EGFR-positive non-small cell lung cancer: a network metaanalysis. <i>Oncotarget</i> , 2016, 7, 20093-20108.  | 0.8 | 31        |
| 23 | A Large-scale Cross-sectional Study of ALK Rearrangements and EGFR Mutations in Non-small-cell Lung Cancer in Chinese Han Population. <i>Scientific Reports</i> , 2014, 4, 7268.  | 1.6 | 28        |
| 24 | Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis. , 2020, 8, e001170.  |     | 28        |
| 25 | Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting: A Network Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw217.  | 3.0 | 26        |
| 26 | A Phase I/II Open-Label Study of Nivolumab in Previously Treated Advanced or Recurrent Nasopharyngeal Carcinoma and Other Solid Tumors. <i>Oncologist</i> , 2019, 24, 891-e431.   | 1.9 | 25        |
| 27 | Risk of second primary malignancy after non-small cell lung cancer: a competing risk nomogram based on the SEER database. <i>Annals of Translational Medicine</i> , 2019, 7, 439-439.   | 0.7 | 25        |
| 28 | Multi-Targeted Antiangiogenic Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer: Meta-Analyses of 20 Randomized Controlled Trials and Subgroup Analyses. <i>PLoS ONE</i> , 2014, 9, e109757.  | 1.1 | 20        |
| 29 | Development and validation of a UPLC-MS/MS method for quantification of osimertinib (AZD9291) and its metabolite AZ5104 in human plasma. <i>Biomedical Chromatography</i> , 2018, 32, e4365.  | 0.8 | 19        |
| 30 | EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients. <i>Clinical and Translational Medicine</i> , 2020, 9, 17.   | 1.7 | 19        |
| 31 | Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis. <i>Oncologist</i> , 2018, 23, 603-616. | 1.9 | 17        |
| 32 | Copy number loss in granzyme genes confers resistance to immune checkpoint inhibitor in nasopharyngeal carcinoma. , 2021, 9, e002014.   |     | 16        |
| 33 | The expression of plakoglobin is a potential prognostic biomarker for patients with surgically resected lung adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 15274-15287.  | 0.8 | 16        |
| 34 | Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials. <i>OncoTargets and Therapy</i> , 2014, 7, 1851.   | 1.0 | 15        |
| 35 | A large, single-center, real-world study of clinicopathological characteristics and treatment in advanced ALK-positive non-small-cell lung cancer. <i>Cancer Medicine</i> , 2017, 6, 953-961.   | 1.3 | 15        |
| 36 | Impact of prior cancer history on the overall survival of younger patients with lung cancer. <i>ESMO Open</i> , 2020, 5, e000608.   | 2.0 | 15        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Anti-epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma. <i>Cancer Medicine</i> , 2020, 9, 1721-1732.  | 1.3 | 15        |
| 38 | The preliminary efficacy and safety data of KN046 in patients failed on prior immune checkpoint inhibitors therapy. <i>Journal of Clinical Oncology</i> , 2020, 38, 3020-3020.   | 0.8 | 15        |
| 39 | Alcohol and survival in ESCC: Prediagnosis alcohol consumption and postoperative survival in lymph node-negative esophageal carcinoma patients. <i>Oncotarget</i> , 2016, 7, 38857-38863.  | 0.8 | 15        |
| 40 | Inflammation-based prognostic system predicts postoperative survival of esophageal carcinoma patients with normal preoperative serum carcinoembryonic antigen and squamous cell carcinoma antigen levels. <i>World Journal of Surgical Oncology</i> , 2016, 14, 141. | 0.8 | 14        |
| 41 | Therapeutic Efficacy Comparison of 5 Major EGFR-TKIs in Advanced EGFR-positive Non-Small-cell Lung Cancer: A Network Meta-analysis Based on Head-to-Head Trials. <i>Clinical Lung Cancer</i> , 2017, 18, e333-e340.  | 1.1 | 14        |
| 42 | Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first-line treatment for advanced EGFR-mutant non-small cell lung cancer. <i>Clinical and Translational Medicine</i> , 2020, 10, e33.                   | 1.7 | 13        |
| 43 | An investigation of symptom burden and quality of life in Chinese chemo-naïve advanced lung cancer patients by using the Instrument-Cloud QOL System. <i>Lung Cancer</i> , 2014, 84, 301-306.  | 0.9 | 12        |
| 44 | Combinatorial assessment of ctDNA release and mutational burden predicts anti-PD(L)1 therapy outcome in non-small cell lung cancer. <i>Clinical and Translational Medicine</i> , 2020, 10, 331-336.  | 1.7 | 12        |
| 45 | Anticancer bispecific antibody R&D advances: a study focusing on research trend worldwide and in China. <i>Journal of Hematology and Oncology</i> , 2021, 14, 124.   | 6.9 | 12        |
| 46 | FOXM1 Variant Contributes to Gefitinib Resistance via Activating Wnt/ $\beta$ -Catenin Signal Pathway in Patients with Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3770-3784.  | 3.2 | 12        |
| 47 | KEYNOTE-032: A Randomized Phase I Study of Pembrolizumab in Chinese Patients with Advanced Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2020, 25, 650-e1145.  | 1.9 | 11        |
| 48 | EGFR mutation genotypes affect efficacy and resistance mechanisms of osimertinib in T790M-positive NSCLC patients. <i>Translational Lung Cancer Research</i> , 2020, 9, 471-483.   | 1.3 | 11        |
| 49 | The analysis of pharmacokinetic and pharmacogenomic impact on gefitinib efficacy in advanced non-small cell lung cancer patients: results from a prospective cohort study. <i>Annals of Translational Medicine</i> , 2019, 7, 806-806.                               | 0.7 | 11        |
| 50 | Docosapentaenoic acid and lung cancer risk: A Mendelian randomization study. <i>Cancer Medicine</i> , 2019, 8, 1817-1825.  | 1.3 | 10        |
| 51 | Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591989165.                                   | 1.4 | 10        |
| 52 | Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer. <i>International Journal of Cancer</i> , 2019, 144, 2854-2866.   | 2.3 | 10        |
| 53 | Baseline and early changes in circulating Serum Amyloid A (SAA) predict survival outcomes in advanced non-small cell lung cancer patients treated with Anti-PD-1/PD-L1 monotherapy. <i>Lung Cancer</i> , 2021, 158, 1-8.   | 0.9 | 10        |
| 54 | Pharmacokinetic and Pharmacodynamic Analyses of 5-Fluorouracil in East-Asian Patients with Nasopharyngeal Carcinoma. <i>Clinical Pharmacokinetics</i> , 2016, 55, 1205-1216.   | 1.6 | 9         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Establishment and application of a predictive model for gefitinib-induced severe rash based on pharmacometabolomic profiling and polymorphisms of transporters in non-small cell lung cancer. <i>Translational Oncology</i> , 2021, 14, 100951.   | 1.7 | 9         |
| 56 | Multi-targeted tyrosine kinase inhibitors as third-line regimen in advanced non-small cell lung cancer: a network meta-analysis. <i>Annals of Translational Medicine</i> , 2019, 7, 452-452.  | 0.7 | 9         |
| 57 | The comparison of EGFR-TKI failure modes and subsequent management between exon 19 deletion and exon 21 L858R mutation in advanced non-small-cell lung cancer. <i>Journal of Cancer</i> , 2017, 8, 1865-1871.   | 1.2 | 8         |
| 58 | Mendelian randomization study indicates lack of causal relationship between physical activity and lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 177-181.  | 1.2 | 8         |
| 59 | Impact of prior cancer on outcomes in nasopharyngeal carcinoma. <i>Annals of Translational Medicine</i> , 2019, 7, 299-299.   | 0.7 | 8         |
| 60 | Cause-specific death assessment of patients with stage I small-cell lung cancer: a competing risk analysis. <i>Future Oncology</i> , 2019, 15, 2479-2488.   | 1.1 | 7         |
| 61 | Clinical pharmacokinetics and drug exposure-toxicity correlation study of docetaxel based chemotherapy in Chinese head and neck cancer patients. <i>Annals of Translational Medicine</i> , 2020, 8, 236-236.  | 0.7 | 7         |
| 62 | Lymphocyte activating gene 3 protein expression in nasopharyngeal carcinoma is correlated with programmed cell death-1 and programmed cell death ligand-1, tumor-infiltrating lymphocytes. <i>Cancer Cell International</i> , 2021, 21, 458.  | 1.8 | 7         |
| 63 | Anticancer drug R&D landscape in China. <i>Journal of Hematology and Oncology</i> , 2020, 13, 51.   | 6.9 | 6         |
| 64 | Distinct Functional Metagenomic Markers Predict the Responsiveness to Anti-PD-1 Therapy in Chinese Non-Small Cell Lung Cancer Patients. <i>Frontiers in Oncology</i> , 2022, 12, 837525.  | 1.3 | 6         |
| 65 | Clinical Significance of Kinetics of Low-Density Lipoprotein Cholesterol and Its Prognostic Value in Limited Stage Small Cell Lung Cancer Patients. <i>Cancer Control</i> , 2021, 28, 107327482110282.  | 0.7 | 5         |
| 66 | Therapeutic drug monitoring of docetaxel by pharmacokinetics and pharmacogenetics: A randomized clinical trial of AUC <sub>0-24</sub> -guided dosing in nonsmall cell lung cancer. <i>Clinical and Translational Medicine</i> , 2021, 11, e354.   | 1.7 | 5         |
| 67 | Emerging immunological strategies: recent advances and future directions. <i>Frontiers of Medicine</i> , 2021, 15, 805-828.   | 1.5 | 5         |
| 68 | First-in-human phase I results of APG-2449, a novel FAK and third-generation ALK/ ROS1 tyrosine kinase inhibitor (TKI), in patients (pts) with second-generation TKI-resistant ALK/ROS1 <sup>+</sup> non-small cell lung cancer (NSCLC) or mesothelioma. <i>Journal of Clinical Oncology</i> , 2022, 40, 9071-9071. | 0.8 | 5         |
| 69 | Phase Ia dose escalation of IBI318, a first-in-class bispecific anti-PD-1/PD-L1, in patients with advanced tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 3062-3062.   | 0.8 | 4         |
| 70 | A phase I, dose-escalation and expansion study of TQ-B3139, a novel ALK TKI, in Chinese ALK or ROS1 positive advanced non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2020, 38, 9585-9585.  | 0.8 | 4         |
| 71 | Determinants of survival in advanced non-small cell lung cancer patients treated with anti-PD-1/PD-L1 therapy. <i>Annals of Translational Medicine</i> , 2021, 9, 1639-1639.  | 0.7 | 4         |
| 72 | Incidence and risk factors of second primary cancer after the initial primary human papillomavirus related neoplasms. <i>MedComm</i> , 2020, 1, 400-409.  | 3.1 | 3         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | Afatinib as a Potential Therapeutic Option for Patients With NSCLC With EGFR G724S. JTO Clinical and Research Reports, 2021, 2, 100193.  | 0.6 | 3         |
| 74 | Time to raise the bar: Transition rate of phase 1 programs on anticancer drugs. Cancer Cell, 2022, 40, 233-235.  | 7.7 | 3         |
| 75 | Ongoing Phase I Studies of Immune Checkpoint Inhibitors in China. Oncologist, 2019, 24, S11-S20.   | 1.9 | 2         |
| 76 | A phase Ib study of a novel c-MET, AXL and VEGFR-2 inhibitor ningetinib and gefitinib combination therapy in Chinese EGFR-TKI resistant NSCLC with T790M negative.. Journal of Clinical Oncology, 2020, 38, 9583-9583.   | 0.8 | 2         |
| 77 | Modification of the tumor response threshold in patients of advanced non-small cell lung cancer treated with chemotherapy plus targeted agents: a pooled study from five clinical trials in one institution. Annals of Translational Medicine, 2019, 7, 253-253. | 0.7 | 1         |
| 78 | Myeloid cell leukemia-1 is an important predictor of survival and progression of small cell lung cancer. Annals of Translational Medicine, 2020, 8, 1589-1589.   | 0.7 | 1         |
| 79 | Reducing number of target lesions for RECIST1.1 to predict survivals in patients with advanced non-small-cell lung cancer undergoing anti-PD1/PD-L1 monotherapy. Lung Cancer, 2022, 165, 10-17.  | 0.9 | 1         |
| 80 | Predictive Value of High Preoperative Serum Total Protein and Elevated Hematocrit in Patients with Non-Small-Cell Lung Cancer after Radical Resection. Nutrition and Cancer, 0, , 1-13.  | 0.9 | 1         |
| 81 | Response to: The Role of Dual Inhibition of EGFR and Vascular EGF(R) in the Treatment of NSCLC With EGFR Mutation. Journal of Thoracic Oncology, 2021, 16, e72-e76.  | 0.5 | 0         |
| 82 | Response to "Limitations of the Hazard Ratio as a Summary Measure in Cancer Clinical Trials". Journal of Thoracic Oncology, 2021, 16, e87-e88.   | 0.5 | 0         |
| 83 | Updated study results of pelcitoclax (APG-1252) in combination with osimertinib in patients (pts) with EGFR-mutant non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2022, 40, 9116-9116.   | 0.8 | 0         |